| Sophia Genetics–SEVERAL: investment, 201407 financing round Series B $13.75m led by Invoke Capital + Endeavour Vision + Swisscom |
2014-07-08 |
| Analyticon Discovery–BRAIN: investment, 201407 acquisition of majority share €na by BRAIN w remaining shares held by management + key personnel |
2014-07-03 |
| Miacom Diagnostics–Fosun: investment, 201407 acquisition of 37% share by Shanghai Fosun Pharmaceutical Group |
2014-07-02 |
| Seragon Pharmaceuticals–Roche: investment, 201407–201408 acquisition $725m upfront cash + $1b milestones by Genentech |
2014-07-02 |
| AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie |
2014-07-01 |
| GeneWeave–SEVERAL: investment, 201407 financing round Series B $12m from Decheng Capital + Claremont Creek Ventures + XSeed Capital |
2014-07-01 |
| Qiagen–Altano Diagnostics: real-time PCR test, 201412– distribution ww of RealStar Ebolavirus RT-PCR Kit 1.0 by Qiagen |
2014-07-01 |
| Qiagen–Altano Diagnostics: real-time PCR test, 2014Q3– distribution of RealStar Filovirus RT-PCR Kit by Qiagen outside US |
2014-07-01 |
| Santhera–SEVERAL: investment, 201407–201408 sale CHF13.4m of 200k treasury common shares at CHF66.85/share |
2014-07-01 |
| RedHill Biopharma–Wilex: upamostat, 201406– license excl ww for Mesupron outside Greater China $1m upfront + royalties of up to 30% on net revenues |
2014-06-30 |
| Medigene–SEVERAL: investment, 201406–201407 capital increase €15.9m 3m new shares + 818.7k convertible bonds |
2014-06-27 |
| GW Pharmaceuticals–SEVERAL: investment, 201406 public offering $126.3m with 1.455m ADSs at $86.83/ADS at Nasdaq |
2014-06-25 |
| Merck (DE)–Mersana: ADC technology, 201406– collab €na using Flemixer technology to develop ADCs |
2014-06-24 |
| Argenx–SEVERAL: investment, 201406–201408 IPO €41.8m 4.7m+0.2m shares at €8.5/shares at Euronext Brussels |
2014-06-23 |
| Bayer–Dimension Therapeutics: gene therapy, 201406– collab €20m upfront + $232m milestones + royalties developm of Hemophilia A gene therapy |
2014-06-23 |
| CytoTools–Instinctif Partners: public relations, 201406 service existent by Instinctif Partners |
2014-06-23 |
| CytoTools–SEVERAL: investment, 201406 capital increase €1.7m of CytoPharma GmbH incl €0.3m from >40% owner CytoTools |
2014-06-23 |
| Definiens–SEVERAL: investment, 201406 financing round €15m led by Wellington Partners + co-led by Gilde Healthcare |
2014-06-23 |
| Dimension Therapeutics–SEVERAL: investment, 201406 financing round $30m from OrbiMed + Fidelity Biosciences |
2014-06-23 |
| Paion–SEVERAL: investment, 201406–201407 capital increase €46.26m placement of 18.5m new shares €2.5/share |
2014-06-18 |
| Thermo Fisher–Excellims: ion mobility spectrometer, 201406 collab co-developm + product integration of MA3100 HPIMS with Orbitrap-based MS systems |
2014-06-16 |
| Univ Copenhagen–Thermo Fisher: mass spectrometer, 201406 supply existent Jesper Olsen at NNF CPR has been early-access user of Q Exactive HF system |
2014-06-16 |
| Covidien–Medtronic: investment, 201406– acquisition $42.9b in cash + shares ANNOUNCED |
2014-06-15 |
| Merck (DE)–MorphoSys: antibody cancer drug, 201406– strategic collab €na using Ylanthia to identify MAbs against immune checkpoints in cancer |
2014-06-12 |
| Genkyotex–Halsin Partners: public relations, 201406 service existent by Halsin Partners |
2014-06-11 |
| Idenix–Merck (US): investment, 201406– acquisition $3.85b cash tender offer $24.5/share ANNOUNCED |
2014-06-09 |
| 4SC–Strüngmann Group: credit, 201406–201612 loan of up to €10m w 8% interest from Santo Holding (Deutschland) GmbH |
2014-06-05 |
| Genia–Roche: investment, 201406 acquisition $125m in cash + $225m milestones ANNOUNCED |
2014-06-02 |
| B Braun–CeGaT: personalised medicine, 201406 collab establishment of B Braun CeGaT LLC in Pennsylvania |
2014-06-01 |
| Luphos–AMETEK: investment, 201405 acquisition of Luphos GmbH by AMETEK |
2014-05-30 |
| Bayer–Argenx: antibody technology, 201405– collab use of SIMPLE Antibody platform to discover + develop therap antibodies against Bayer targets |
2014-05-28 |
| Euprotec–Evotec: investment, 201405 acquisition 100% for £1.9m cash upfront + deferred business performace-based payment |
2014-05-28 |
| GSK–Genedata: Genedata Biologics, 201405– supply + collab GSK Biopharm RnD |
2014-05-28 |
| Roche–Stratos: DNA sequencing technology, 201405– collab r+d of SBX technology incl strategic investment by Roche |
2014-05-26 |
| Stratos–Roche: investment, 201405 strategic investment in Stratos Genomics in connection with collab on SBX technology |
2014-05-26 |
| Neuway Pharma–SEVERAL: investment, 201405 financing round Series A €2.7m led by Wellington Partners |
2014-05-25 |
| Neuway Pharma–Wellington Partners: investment, 201405 financing round Series A totalling €2.7m led by Wellington Partners |
2014-05-25 |
| Affimed–SEVERAL: investment, 201405–201409 IPO $56m+$8.4m offering 8m+1.2m common shares $7/share at Nasdaq |
2014-05-23 |
| Biobase–Qiagen: investment, 201405 acquisition €na by Qiagen |
2014-05-20 |
| Merck (DE)–Sysmex: molecular companion diagnostics, 201405– collab developm + commercialisation blood-based RAS biomarker mutation status test |
2014-05-19 |
| Bayer–Boston Scientific: investment, 201405–201409 acquisition $415m of interventional device business by Boston Scientific |
2014-05-15 |
| Co.don–SEVERAL: investment, 201405 capital increase €5m 2.6m new shares €1.9/share |
2014-05-15 |
| Thermo Fisher–Evans Analytical: ionisation technology, 201405– collab developm pulsed ion source technology for glow discharge MS |
2014-05-14 |
| Locate Therapeutics–Heraeus: investment, 201405 undisclosed investment €na by Heraeus |
2014-05-09 |
| Affymetrix–Danaher: lab automation, –201405 collab product integration fully automated ViewRNA eZ Assays on Leica BOND RX staining platform |
2014-05-08 |
| ImaginAb–SEVERAL: investment, 201405 financing round Series B $21m led by Mérieux Développement |
2014-05-08 |
| Lophius–SEVERAL: investment, 201405 financing round €2m VRD GmbH + S-Refit + another existing investor |
2014-05-08 |
| Eternygen–Evotec: drug discovery services, 201405– colllab identification + developm small-molecule inhibitors agianst target in metoblic disease |
2014-05-06 |
| Anokion–SEVERAL: investment, 201405 financing round Series A CHF33m ($37.5m) led by Novartis Venture + Novo Ventures + Versant Ventures |
2014-05-05 |
| Bayer–Cenix BioScience: drug target discovery, 201405– supply research service €na RNAi-based techn to identify targets for undisclosed indication |
2014-05-05 |
| Novartis–Ophthotech: pegpleranib, 201405– excl license + commercialisation agreem outside of US |
2014-05-01 |
| OptiBioCat project–EU (govt): grant, 201405– FP7 grant €7m to develop biocatalysts for cosmetics production |
2014-05-01 |
| Quantapore–SEVERAL: investment, 201405 financing round Series B up to $35m from undisclosed investors |
2014-05-01 |
| SomPharmaceuticals–SEVERAL: investment, 201404 private placement CHF750k Series A |
2014-04-29 |
| AllPure Technologies–Sartorius: investment, 201404– acquisition of majority stake €na by Sartorius Stedim Biotech signed |
2014-04-28 |
| CytoTools–SEVERAL: investment, 201404 capital increase €2.3m of DermaTools Biotech GmbH from mother CytoTools + existing investor |
2014-04-28 |
| Merck (US)–Agenus: antibody cancer drug, 201402– collab + license up to $100m milestones + royalties use of 4-Antibody Retrocyte Display technology |
2014-04-28 |
| Sequana Medical–SEVERAL: investment, 201404 financing round Series C CHF23m ($26.2m) led by LSP with NeoMed remaing largest investor |
2014-04-28 |
| Filgen–Metabolomic Discoveries: metabolomics, 201404– distribution excl of Metabolomic Discoveries’ technologies in Japan by Filgen |
2014-04-25 |
| Biobase–Murdoch Childrens Research Institute: POSSUMweb database, 201404– distribution ww excl by Biobase GmbH |
2014-04-24 |
| Boehringer–Hydra Biosciences: CNS drugs, 201404– collab ww r+d small-molecule TRPC4/5 inhibitors for CNS diseases |
2014-04-24 |
| Clal Industries–Hyperion Therapeutics: investment, 201404–201406 acquisition of Andromeda Biotech for $12.5m in cash + 313k shares |
2014-04-24 |
| CRISPR Therapeutics–Versant Ventures: investment, 201404 financing round Series A $25m from Versant Ventures |
2014-04-24 |
| Isarna Therapeutics–SEVERAL: investment, 201404 financing round €5.5m from existing investors incl ATNewTec + Global Asset Fonds + MIG |
2014-04-24 |
| European ScreeningPort–Fraunhofer: investment, 201406 restructuring of ESP becoming part of Fraunhofer IME |
2014-04-23 |
| GSK–Novartis: OTC drugs, 201404–201503 collab establishment of OTC joint venture with Novartis owning 36.5% |
2014-04-22 |
| Novartis–GSK: cancer drugs, 201404–201503 acquisition $14.5b + $1.5b milestones of GSK oncology products + opt in GSK oncology pipeline |
2014-04-22 |
| Novartis–GSK: investment, 201404–201503 acquisition $5.25b upfront + $1.8b milestones + royalties of Novartis vaccine business excluding flu business |
2014-04-22 |
| Novartis–Lilly: investment, 201404–201501 acquisition $5.4b in cash of Novartis Animal Health Divison by Eli Lilly |
2014-04-22 |
| High-Tech Gründerfonds–Bayer: investment, 201404 investment of Bayer Pharma AG in High-Tech Gründerfonds II |
2014-04-19 |
| Daiichi Sankyo–Max Planck: drug discovery services, 201404– supply screening services by LDC using LDC + Daiichi compound libraries |
2014-04-17 |
| 4SC–EU (govt): grant, 201404– €450k grant for 4SC Discovery GmbH as part of the CV genes-at-target project |
2014-04-15 |
| Biocartis–Danaher: Evalution multiplex detection platform, 201404– collab + supply co-developm + manufacturing by Invetech |
2014-04-15 |
| Essen BioScience–SFW Capital Partners: investment, 201405 strategic investment in Essen BioScience by SFW |
2014-04-15 |
| Diana–Symrise: investment, 201404– planned acquisition €1.3b ANNOUNCED |
2014-04-12 |
| Qiagen–Austrian Academy of Sciences: biomarker, 201404– license excl ww to biomarker calreticulin (CALR) from CeMM Vienna |
2014-04-10 |
| Omni Life Science–ACEA Biosciences: cell analysis technology, 201404 collab OLS is excl distributor for ACEA in Austria |
2014-04-09 |
| Omni Life Science–ACEA Biosciences: cell analysis technology, 201404 collab OLS is excl distributor for ACEA in Germany |
2014-04-09 |
| Piqur Therapeutics–SEVERAL: investment, 201404 financing round Series A extension CHF18m led by Versant Ventures with CHF11m |
2014-04-08 |
| Piqur Therapeutics–Versant Ventures: investment, 201404 financing round Series A extension totalling CHF18m incl CHF11m from Versant Ventures |
2014-04-08 |
| IQuum–Roche: investment, 201404 acquisition $275m upfront + $175m milestones |
2014-04-07 |
| Roche–Oryzon Genomics: LSD1 inhibitors, 201404–201707 collab $21m upfront + short-term milestones + $500m milestones + royalties TERMINATED 7/17 |
2014-04-07 |
| Roche–Oryzon Genomics: LSD1 inhibitors, 201605–201707 collab extension developm of ORY-1001 TERMINATED 7/17 |
2014-04-07 |
| Merck (DE)–Auxogyn: IVF test, 201404– license excl for commercialisation of Eeva Test in Europe + Canada to Merck Serono |
2014-04-03 |
| Debiopharm–Evotec: drug discovery services, 201404– collab + licensing discovery + developm of cancer drugs |
2014-04-02 |
| Bayer–Targenomix: plant target discovery, 201404–201903 collab 5y to discover molecular targets in plants using systems biology |
2014-04-01 |
| EcoMetals project–BRAIN: industrial biotechnology, 201404– collab BRAIN AG is industrial project partner in German-French EcoMetals research programme |
2014-04-01 |
| EcoMetals project–Germany (govt): grant, 201404– funding €4,2m from BMBF for 7 German project partners |
2014-04-01 |
| EcoMetals project–Helmholtz: industrial biotechnology, 201404– collab HZDR is lead scientific project partner in EcoMetals research programme |
2014-04-01 |
| Pierre Fabre–Affimed: antibody technology, 201404– collab use of AbCheck’s AbSieve discovery platform to discover ABs against targets of CIPF |
2014-04-01 |
| Roche–Hitachi: immunoassay + chemical analyser, 201404–202403 collab strategic alliance developm + production 10y extension |
2014-04-01 |
| Trinean–Sony: microfluidics disposables, 201404– supply OEM for DropSense96 spectrometer + Xpose Touch&Go sample QC analyzer by Sony DADC BioSciences |
2014-04-01 |
| Convergence Pharmaceuticals–Evotec: drug discovery services, 201403– collab €na pain drug r+d with Panion Ltd |
2014-03-31 |
| Convergence Pharmaceuticals–United Kingdom (govt): grant, 201403c– Biomedical Catalyst grant £2.4m to develop drug against novel GPCR pain target |
2014-03-31 |
| Singulex–Sony: microtitre plates, 201403– supply of customised detection vessels as microtitre plate for Sgx Clarity System by Sony DADC BioSciences |
2014-03-31 |
| Anatech Instruments–Fortis Technologies: HPLC columns, 201403 distribution existent in South Africa by Anatech Instruments |
2014-03-29 |
| Dichrom–Fortis Technologies: HPLC columns, 201403 distribution existent in Germany by Dichrom |
2014-03-29 |
| Genmab–MAB Discovery: drug discovery services, 201403– collab €na generation of antibodies for multiple Genmab targets |
2014-03-27 |
| MAB Discovery–MC Services: public relations, 201403 service existent for MAB Discovery GmbH |
2014-03-27 |
| Singulex–Tecan: automated liquid handling, 201403– collab developm of Sgx Clarity System using Freedom EVO platform |
2014-03-25 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
1 2 3 ... 31 32 33 ... 53 54 55 
Date![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
